BindingDB logo
myBDB logout

140 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
9873384 15 Design and synthesis of an orally active GPIIb/IIIa antagonist based on a phenylpiperazine scaffold.EBI Solvay Pharma
27662032 33 Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.EBI China Pharmaceutical University
26912112 6 Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrinaIIb▀3.EBI A.V. Bogatsky Physico-Chemical Institute of the National Academy of Sciences of Ukraine
24949551 22 Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.EBI Philipps-Universit£t Marburg
24654918 19 Pharmacophoric modifications lead to superpotentav▀3 integrin ligands with suppresseda5▀1 activity.EBI Technische Universit£t M£nchen
23757209 10 Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrinaIIb▀3.EBI A.V. Bogatsky Physico-Chemical Institute of the National Academy of Sciences of Ukraine
23644213 57 Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.EBI University of Ljubljana
23376251 32 Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.EBI University of Ljubljana
23362923 59 Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.EBI Technische Universit£t M£nchen
19959360 50 SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.EBI Jerini AG
19910191 46 Discovery of orally available integrin alpha5beta1 antagonists.EBI Jerini AG
8960563 12 Quantitative structure-activity relationship study of fibrinogen inhibitors, [[4-(4-amidinophenoxy)butanoyl]aspartyl]valine (FK633) derivatives, using a novel hydrophobic descriptor.EBI Fujisawa Pharmaceutical Company Ltd.
10853647 63 Three-dimensional quantitative structure-activity relationship analyses of RGD mimetics as fibrinogen receptor antagonists.EBI Kyoto University
 9 Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorEBI TBA
8893849 10 Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha V beta 3 receptor.EBI Texas A& M University
7650686 3 Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.EBI Merck Research Laboratories
11738566 20 Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.EBI Merck Research Laboratories
22575869 61 Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.EBI AstraZeneca
19860432 42 alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.EBI Universite Catholique de Louvain
18068982 20 Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates.EBI BASF AG
16134928 34 Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.EBI The Scripps Research Institute
15857114 11 Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities.EBI University of Ljubljana
15482918 10 Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid.EBI A.V. Bogatsky Physico-Chemical Institute of the National Academy of Sciences of Ukraine
15357991 20 Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.EBI 3-Dimensional Pharmaceuticals, Inc
12139455 78 Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.EBI Genentech Inc.
11543674 3 Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin alphaIIbbeta3.EBI University of Hamburg
10999999 83 Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.EBI COR Therapeutics, Inc.
9622548 8 Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.EBI 3-Dimensional Pharmaceuticals Inc.
9207948 65 Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.EBI DuPont Merck Pharmaceutical Company
9191954 9 Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.EBI Merck Research Laboratories
7608903 29 Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists.EBI Searle Research& Development
7837237 37 Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation.EBI R. W. Johnson Pharmaceutical Research Institute
1479591 8 Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor.EBI Searle Research& Development
1597855 194 Cyclic RGD peptide analogues as antiplatelet antithrombotics.EBI Genentech
10673106 28 RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements.EBI Hoechst Marion Roussel Deutschland GmhH
 10 Synthesis, evaluation and Tc-99m complexation of a hydrazinonicotinyl conjugate of a GP IIb/IIIa antagonist cyclic peptide for the detection of deep vein thrombosisEBI TBA
 18 Design, synthesis, and evaluation of fibrinogen inhibitors, -(p-amidinophenoxy) alkanoylaspartic acid derivativesEBI TBA
 3 Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicalsEBI TBA
22185640 15 Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site.EBI Technische Universit£t M£nchen
22365562 154 Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.EBI University of Ljubljana
21344906 54 Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.EBI The University of Tokyo
 12 Beta-amino acid derivatives as orally active non-peptide fibrinogen receptor antagonistsEBI TBA
 41 Dihydroisoquinolone RGD mimics. Exploration of the aspartate isostereEBI TBA
 24 Tetrahydrothienopyridine derivatives as novel GPIIb/IIIa antagonistsEBI TBA
 18 Nonpeptide GPIIb/IIIa inhibitors. 10. Centrally constrained alpha-sulfonamides are potent inhibitors of platelet aggregationEBI TBA
 17 Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine seriesEBI TBA
 54 Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042EBI TBA
 17 Non-peptide fibrinogen receptor antagonists based upon a 4-substituted piperidine scaffoldEBI TBA
 12 Platelet glycoprotein IIb–IIIa receptor (GPIIb–IIIa) antagonists derived from amidinoindolesEBI TBA
 13 Non-peptide glycoprotein IIb/IIIa inhibitors. 6. Design and synthesis of rigid, centrally constrained non-peptide fibrinogen receptor antagonistsEBI TBA
 11 Synthesis and antiplatelet activity of DMP 757 analogsEBI TBA
 2 Design, synthesis and SAR of RGD peptide hybrids as highly efficient inhibitors of platelet aggregationEBI TBA
 1 Adamantane and Nipecotic Acid Derivatives as Novel β-Turn MimicsEBI TBA
 17 Fibrinogen receptor antagonists containing a gamma-lactam Gly-Asp isostereEBI TBA
19081719 20 Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5).EBI Pharmacopeia, Inc.
18729445 70 3,4-Dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function.EBI University of Ljubljana
17973471 24 Multiple N-methylation by a designed approach enhances receptor selectivity.EBI Technische Universität München
17910915 19 Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.EBI Bayer Healthcare AG
17616113 63 Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.EBI Jerini AG
16621534 87 Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.EBI Pfizer Inc.
16303301 44 Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.EBI Pfizer Global Research and Development
16298127 80 Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.EBI Pfizer Inc.
15974570 30 Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.EBI Università di Napoli Federico II
15745815 7 Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.EBI Merck Research Laboratories
15715463 16 Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.EBI Johnson and Johnson Pharmaceutical Research & Development
15501072 58 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.EBI Johnson & Johnson Pharmaceutical Research & Development
15380233 46 Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.EBI Johnson & Johnson Pharmaceutical Research and Development
15125957 23 N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.EBI Amgen Inc.
15109653 30 Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model.EBI Dainippon Pharmaceutical Co., Ltd
15056002 112 Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.EBI Millennium Pharmaceuticals Inc.
15006384 179 Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.EBI Pfizer Inc.
14741263 67 Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.EBI Nerviano
14698164 39 Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.EBI Pharmaceutical Research Institute
14640540 18 Molecular model of the alpha(IIb)beta(3) integrin.EBI Merck Research Laboratories
14561098 8 Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.EBI Merck Research Laboratories
12729670 49 Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.EBI Merck Research Laboratories
12668017 17 Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.EBI GlaxoSmithKline Pharmaceuticals
12565960 33 Thiophene-based vitronectin receptor antagonists.EBI Shire BioChem Inc.
12565923 6 Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors.EBI Leiden University
12482416 52 Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones.EBI BASF AG
12477347 16 Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin.EBI Merck Research Laboratories
12392735 30 Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.EBI Institut de Recherches Servier
11909727 35 Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes.EBI COR Therapeutics, Inc.
11855984 102 Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.EBI Merck KGaA
11814816 30 Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists.EBI Knoll GmbH
11551763 25 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists.EBI The R. W. Johnson Pharmaceutical Research Institute
11454469 95 alpha(v)beta(3) Antagonists based on a central thiophene scaffold.EBI Aventis Pharma Deutschland GmbH
11392540 23 Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes.EBI COR Therapeutics, Inc
11392539 34 Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.EBI COR Therapeutics, Inc
11384239 82 Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.EBI Technische Universität München
11327582 23 2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.EBI Taisho Pharmaceutical Co. Ltd.
11312916 2 Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold.EBI Aventis Pharma AG
10987423 83 Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.EBI Merck Research Laboratories
10853677 34 Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.EBI Celltech Chiroscience
10743945 21 Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists.EBI DuPont Pharmaceuticals Company
10714506 13 Fused bicyclic Gly-Asp beta-turn mimics with potent affinity for GPIIb-IIIa. Exploration of the arginine isostere.EBI Eli Lilly and Company
10633037 88 Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3).EBI DuPont Pharmaceuticals Company
10633036 79 Isoxazolines as potent antagonists of the integrin alpha(v)beta(3).EBI DuPont Pharmaceuticals Company
10633035 20 Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.EBI SmithKline Beecham Pharmaceuticals
10602710 51 Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.EBI The R. W. Johnson Pharmaceutical Research Institute
10579850 15 Fused bicyclic Gly-Asp beta-turn mimics with specific affinity for GPIIb-IIIa.EBI Eli Lilly and Company
10447947 14 N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.EBI Technische Universität München
10406646 15 Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.EBI SmithKline Beecham Pharmaceuticals
10406645 36 Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.EBI SmithKline Beecham Pharmaceuticals
10395482 40 Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.EBI Merck Research Laboratories
10230615 60 Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of alphavbeta3 antagonists lead compounds.EBI Du Pont Pharmaceuticals Company
10206551 15 Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitors.EBI Merck Research Laboratories
10197962 13 Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.EBI The DuPont Merck Pharmaceutical Company
10072689 39 Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.EBI Biogen Inc.
10052962 21 Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.EBI SmithKline Beecham Pharmaceuticals
10021912 32 Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate.EBI DuPont Pharmaceuticals Company
9873696 80 Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.EBI SmithKline Beecham Pharmaceuticals
9767641 11 New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.EBI Mitsui Pharmaceuticals Inc.
9651154 54 Design of a new class of orally active fibrinogen receptor antagonists.EBI Rhône-Poulenc Rorer Central Research
9632368 30 GPIIb/IIIa integrin antagonists with the new conformational restriction unit, trisubstituted beta-amino acid derivatives, and a substituted benzamidine structure.EBI Nippon Steel Corporation
9484499 94 Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.EBI Takeda Chemical Industries, Ltd.
9435900 89 Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.EBI COR Therapeutics, Inc.
9341914 15 New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.EBI Sanofi Recherche
9288166 74 Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.EBI Lilly Research Laboratories
9240343 28 Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.EBI SmithKline Beecham Pharmaceuticals
9207949 26 Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa.EBI Lilly Research Laboratories
9057858 23 From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus.EBI Genentech
9016328 19 Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.EBI DuPont Merck Pharmaceutical Company
8960544 10 Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.EBI SmithKline Beecham Pharmaceuticals
8759635 16 Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.EBI F. Hoffmann-La Roche Ltd.
8667355 2 Discovery of an orally active non-peptide fibrinogen receptor antagonist.EBI Hoechst AG
8145226 45 Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation.EBI SmithKline Beecham Pharmaceuticals Research and Development
8057299 66 Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.EBI Merck Research Laboratories
7837245 4 Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore.EBI SmithKline Beecham Pharmaceuticals
7752183 22 Design and evaluation of nonpeptide fibrinogen gamma-chain based GPIIb/IIIa antagonists.EBI R. W. Johnson Pharmaceutical Research Institute
7507165 139 Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.EBI Telios Pharmaceuticals, Inc.
1920361 52 Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.EBI SmithKline Beecham Pharmaceuticals Research and Development
1469694 22 Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.EBI Merck Research Laboratories
1433204 10 Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists.EBI SmithKline Beecham Pharmaceuticals
1433203 20 Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides.EBI SmithKline Beecham Pharmaceuticals
18408714 25 Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.BDB The Medical School, Newcastle University